Humberto Sasieta, MD
Pulmonary Disease · Houston, TXNPI 1780972497
Payments from drug & device makers
Across 401 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- GSK$1K
- AstraZeneca$1K
- Olympus Corporation Of The Americas$820
- Electromed, Inc.$757
- Sanofi$610
- plus $3K from 30 others
What the payments were for
- Travel & lodging$1,19313%
- Food & beverage$7,89785%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 41 | $1,518 |
| GSK | 74 | $1,402 |
| AstraZeneca | 33 | $1,043 |
| Olympus Corporation Of The Americas | 6 | $820 |
| Electromed, Inc. | 89 | $757 |
| Sanofi | 21 | $610 |
| Insmed, Inc. | 21 | $360 |
| Regeneron Healthcare Solutions, Inc. | 16 | $331 |
| Actelion Pharmaceuticals US, Inc. | 12 | $316 |
| Mylan Specialty L.p. | 8 | $269 |
| Harmony Biosciences LLC | 9 | $264 |
| Jazz Pharmaceuticals Inc. | 3 | $221 |
| Philips North America LLC | 13 | $212 |
| Amgen | 12 | $204 |
| Melinta Therapeutics, LLC | 1 | $110 |
| Rigel Pharmaceuticals, Inc. | 4 | $93 |
| Pulmonx Corporation | 4 | $92 |
| Grifols USA, LLC | 4 | $90 |
| Johnson & Johnson(2 entities) | 3 | $78 |
| Pfizer | 3 | $69 |
| Boehringer Ingelheim | 3 | $45 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Resmed Corp | 2 | $41 |
| United Therapeutics Corporation | 5 | $32 |
| Sobi, Inc | 1 | $32 |
| Viatris Specialty LLC | 1 | $31 |
| Bayer | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $21 |
| Inogen, Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Exelixis Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$790
- Olympus Bronchoscopes$740
- Olympus Capital Accessories$740
- Olympus Respiratory Accessories$740
- Inspire$244
- DUPIXENT$189
- TAGRISSO$125
- Wakix$125
- XYREM$122
- AREXVY$115
- Vabomere$110
How this compares
$9,285 in reported general payments places this provider in the 70th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $342,755 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 394 | $280,112 |
| Dupixent PenDupilumab | 32 | $124,704 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $57,800 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 81 | $46,703 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $44,677 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $31,231 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 381 | $10,921 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,583 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,722 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,850 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $4,539 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,431 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $2,295 |
| Ventolin HfaAlbuterol Sulfate | 32 | $2,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $45 | $382,569101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,402 | $378,772595 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,043 | $65,522124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.